Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: Effects of glutamate antagonists

Journal of Neural Transmission

Volumn 106, Issue 3-4, 1999, Pages 283-300

  Fredriksson, A ^a   Palomo, T ^b   Chase, T ^c   Archer, T ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

C57 B1 6 mice; CGP 40116; Chronic injections; L Dopa 20 mg kg; MK 801; MPTP; NMDA antagonists; Parkinsonism; Reinstatement; Suprathreshold; Synergism; Tolerance

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; DIZOCILPINE; DOPAMINE; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG TOLERANCE; LOCOMOTION; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; REARING; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 2-AMINO-5-PHOSPHONOVALERATE; ANIMALS; ANTIPARKINSON AGENTS; DIFFERENTIAL THRESHOLD; DIZOCILPINE MALEATE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMATES; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; N-METHYLASPARTATE; SEXUAL BEHAVIOR, ANIMAL;

EID: 0032944412     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020050158     Document Type: Article

References (56)

1. Ahlskog JE, Muenter MD, McManis PG, Bell GN, Bailey PA (1988) Controllcd-release Sinemet (CR-4): A double-blind crossover study in patients with fluctuating Parkinson's disease. Mayo Clin Proc 63: 876-886
2. Archer T, Fredriksson A, Jonsson G, Lewander T, Mohammed AK, Ross SB, Söderberg U (1986) Central noradrenaline depletion antagonizes aspects of d-amphetamine-induced hyperactivity in the rat. Psychopharmacology 88: 141-146
3. Archer T, Bassen M, Peters D, Luthman J, Fredriksson A (1996) Dopaminergic-glutamatergic balance in the forebrain: Functional studies of movement disorders in rats and mice. In: Beninger RJ, Palomo T, Archer T (eds) Dopamine Disease States. Madrid University Press, Madrid, pp 117-154
4. Barbeau A (1969) L-Dopa therapy in Parkinson's disease: A critical review of nine year's experience. Can Med Assoc J 101: 59-68
5. Björk L, Cornfield LJ, Nelson DL, Hillver S-E, Andén N-E, Lewander T, Hackwell U (1991) Pharmacology of the novel 5-hydroxytryptamine1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin: Inhibition of (R)-8-hydroxy-2-(dipropylamino)tetralin-induced effects. J Pharmacol Exp Ther 258: 58-65
6. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN (1994) Wearing-off fluctuations in Parkinson's disease: Contribution of postsynaptic mechanisms. Ann Neurol 36: 27-31
7. Carlsson M, Carlsson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75: 221-226
8. Chase TN (1998) The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 55 [Suppl 1]: 1-9
9. Chase TN, Mouradian MM, Fabbrini G, Juncos JL (1988) Pathogenetic studies of motor fluctuations in Parkinson's disease. J Neural Transm [Suppl] 27: 3-10
10. Chase TN, Mouradian MM, Engber TM (1993) Motor response complications and the function of striatal efferent systems. Neurology 43 [12 Suppl 6]: 23-27
11. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A (1994) Longtitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease. Neurology 44: 1287-1292
12. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, Kopin IJ (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1: 249-254
13. Duvoisin RC, Heikkila RE, Nicklas WJ, Hess A (1986) Dopaminergic neurotoxicity of MPTP in the mouse: A murine model of parkinsonism In: Fahn S (ed) Recent Developments. Parkinson's Disease. Raven Press, New York, pp 147-156
14. Engber TM, Papa SM, Boldry RC, Chase TN (1994) NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 5: 2586-2588
15. Eriksson T, Magnusson T, Carlsson A, Linde A, Granerus AK (1984) "On-Off" phenomenon in Parkinson's disease: Correlation to the concentration of dopa in plasma. J Neural Transm 59: 229-240
16. Fabbrini G, Juncos JL, Mouradian MM, Serrati C, Chase TN (1987a) Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 21: 370-376
17. Fabbrini G, Juncos JL, Mouradian MM, Serrati C, Chase TN (1987b) 3-O-methyl and motor flucuations in Parkinson's disease. Neurology 37: 856-859
18. Fredriksson A, Archer T (1994) MPTP-induced behavioural and biochemical deficits: A parametric analysis. J Neural Transm [PD Sect] 7: 123-132
19. Fredriksson A, Plaznik A, Sundström E, Jonsson G, Archer T (1990) MPTP-induced hypoactivity in mice: Reversal by L-Dopa. Pharmacol Toxicol 67: 295-301
20. Fredriksson A, Gentsch C, Archer T (1994a) Synergistic interactions between NMDA antagonists and L-Dopa on activity in MPTP-treated mice. J Neural Transm [Gen Sect] 97: 197-209
21. Fredriksson A, Gentsch C, Archer T (1994b) Effect of the competitive NMDA antagonist, CGP 40116, and a low dose of L-Dopa on the motor activity deficit of MPTP-treated mice. Behav Pharmacol 5: 599-606
22. Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK (1991) Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J Pharmacol Exp Ther 257: 691-697
23. Harder S, Baas H, Reitbrock S (1995) Concentration-effect relationship of levodopa in patients with Parkinson's disease. Clin Pharmacokinet 29: 243-256
24. Hoehn MM (1987) Parkinson's disease: Progression and mortality. Adv Neurol 45: 457-461
25. Indo T (1984) Study on the striatal dopamine availability in Parkinson's disease. Jpn J Med 23: 228-236
26. Jensen NO, Dupont E, Hansen E, Mikkelsen B, Mikkelsen BO (1988) A controlled release form of madopar in parkinsonian patients with advanced disease and marked fluctuations in motor performance. Acta Neurol Scand 77: 422-425
27. Jolkkonen J, Jenner P, Marsden CD (1995) Glutamatergic regulation of striatal peptide gene expression in rats. J Neural Transm [PD Sect] 10: 187-198
28. Jonsson G, Nwanze E, Luthman J, Sundström E (1986) Effect of MPTP and its pyridinium mctabolites on monoarnine uptake and on central catecholamine neurons in mice. Acta Physiol Scand 128: 187-194
29. Kannari K, Markstein R (1991) Dopamine antagonists potentiate the antikinetic effects of competitive NMDA-antagonists in monoamine-depleted mice. J Neural Transm [Gen Sect] 84: 211-220
30. Kirk R (1995) Experimental design: Procedurcs for the behavioural sciences. Brooks/ Cole, Belmont, Ca
31. Klockgether T, Turski L (1990) NMDA antagonists potentiate antiparkinsonian actions of L-Dopa in monoamine-depleted rats. Ann Neurol 30: 717-723
32. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980
33. Langston JW, Langston EB, Irwin I (1984) MPTP-induced parkinsonism in human and non-human primates - Clinical and experimental aspects. Acta Neurol Scand 70 [Suppl 100]: 49-54
34. Levy R, Herrero MT, Ruberg M, Villares J, Faucheux B, Guridi J, Guillen J, Luquin MR, Javoy-Agid F, Obeso JA, et al. (1995) Effects of nigrostriatal denervation and L-dopa therapy on GABAergic neurons in the striatum in MPTP-treated monkeys and Parkinson's disease: An in situ hybridization study of GAD67 mRNA. Eur J Neurosci 7: 1199-1209
35. Löschmann PA, Lange KW, Kunow M, Rettig KJ, Jaehnig P, Honore T, Turski L, Wachtel H, Jenner P, Marsden CD (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's discase. J Neural Transm [PD Sect] 3: 203-213
36. Marion MH, Stocchi F, Ouinn NP, Jenner P, Marsden CD (1986) Repeated levodopa infusions in fluctuating Parkinson's disease: Clinical and pharmacological data. Clin Neuropharmacol 9: 165-181
37. May J, Skuza G, Rogoz Z (1993) Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: Potential antiparkinsonian activity. J Neural Transm [PD Sect] 6: 53-62
38. Mizuno Y, Kondo T, Mori H (1994) Various aspects of motor fluctuations and their management in Parkinson's disease. Neurology 44 [7 Suppl 6]: S29-S34
39. Nutt JG, Woodward WR (1986) Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36: 739-744
40. Nutt JG, Woodward WR, Harmnerstad JP, Carter JH, Anderson JL (1984) The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 310: 483-488
41. Nutt JG, Carter JH, Woodward WR (1994) Effect of brief levodopa holidays on the short-duration response to levodopa: Evidence for tolerance to the antiparkinsonian effects. Neurology 44: 1617-1622
42. Ong WY, He Y and Garey LJ (1997) Localisation of glutamate receptors in the substantia nigra pars compacta of the monkey. J Hirnforsch 38: 291-298
43. Papa SM, Chase TN (1996) Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 39: 574-578
44. Papa SM, Engber TM, Kask AM, Chase TN (1994) Motor fluctuations in levodopa treated parkinsonian rats: Relation to lesion extent and treatment duration. Brain Res 662: 69-74
45. Reilly DK, Hershey L, Rivera-Calimlim L, Shoulson I (1983) On-off effects in Parkinson's disease: A controlled investigation of ascorbic acid therapy. Adv Neurol 37: 51-60
46. Rinne UK (1983) Problems associated with long-term levo-dopa treatment of Parkinson's disease. Acta Neurol Scand [Suppl] 95: 19-26
47. Sage JI, Mark MH (1994) Basic mechanisms of motor fluctuations. Neurology [7 Suppl 6]: S10-S14
48. Schmidt WJ, Kretschmer BD (1997) Behavioural pharmacology of glutamate receptors in the basal ganglia. Neurosci Biobehav Rev 21: 381-392
49. Shif M, Kempster PA (1994) Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease. Clin Exp Neurol 31: 38-42
50. Starr MS (1995) Antiparkinsonian actions of glutamate antagonists - Alone and with L-DOPA: A review of evidence and suggestions for possible mechanisms. J Neural Transm [PD Sect] 10: 141-185
51. Striem S, Bar Joseph A, Berkovitch Y, Biegon A (1997) Interaction of dexanabinol (HU-211), a novel NMDA antagonist, with the dopaminergic system. Eur J Pharmacol 338: 205-213
52. Sundström E, Goldstein M, Jonsson G (1986) Uptake inhibition protects nigrostriatal dopamine neurons from the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPP +) in mice. Eur J Pharmacol 131: 289-292
53. Sundström E, Strömberg I, Tsutsumi T, Olson L, Jonsson G (1987) Studies on the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57 BL/6 mice. Comparison with three other strains of mice. Brain Res 405: 26-38
54. Sundström E, Fredriksson A, Archer T (1990) Neurochemical and behavioural changes in MPTP-lesioned C57 BL/6 mice: A model for Parkinson's disease. Brain Res 528: 181-188
55. Verhagen-Metman L, Del-Dotto P, Van den Munckhof P, Fang J, Mouradian MM, Chase TN (1998) Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50: 1323-1326
56. Ye Liu Y, Yu H, Mohell N, Nordvall G, Lewander T, Hacksell U (1995) Derivatives of cis-2-amino-8-hydroxy-1-methyltetralin: Mixed 5-HT1A-receptor agonists and dopamine-D2-receptor antagonists. J Med Chem 38: 150-160